TELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2022 16:02 ET
|
TELA Bio, Inc.
MALVERN, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference
November 21, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Reports Third Quarter 2022 Financial Results
November 09, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum
November 03, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 28, 2022 16:05 ET
|
TELA Bio, Inc.
MALVERN, Pa., Oct. 28, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...
TELA Bio to Announce Third Quarter 2022 Financial Results
October 27, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair
October 26, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical...
TELA Bio to Participate in Upcoming Investor Conferences
September 01, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase
August 23, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 23, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...